Compare SNGX & JWEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNGX | JWEL |
|---|---|---|
| Founded | 1987 | 2012 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 5.7M |
| IPO Year | 2006 | 2020 |
| Metric | SNGX | JWEL |
|---|---|---|
| Price | $0.38 | $1.88 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 334.0K | 1.7K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $119,371.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $1.47 |
| 52 Week High | $6.23 | $3.00 |
| Indicator | SNGX | JWEL |
|---|---|---|
| Relative Strength Index (RSI) | 44.32 | 40.74 |
| Support Level | $0.37 | $1.68 |
| Resistance Level | $0.38 | $2.00 |
| Average True Range (ATR) | 0.02 | 0.04 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 71.54 | 29.62 |
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
Jowell Global Ltd is a cosmetics, health, nutritional supplements, and household products e-commerce platform in China. The company offers its branded products to customers and also sells and distributes products from other companies on its platform. In addition, it allows third parties to open their stores on its platform for a service fee based on their sales revenues generated from their online stores and provides them with information about market needs, enabling them to manage their sales effort, as well as an effective platform to promote their brands. The company currently operates under four sales channels: Online Direct Sales, Authorized Retail Store Distribution, Third-party Merchants, and Live streaming marketing.